Nuvectis Pharma Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Nuvectis Pharma, Inc. (NVCT) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-26.44-19.00-22.26-19.09-12.89-0.02
Stock Based Compensation1.354.864.711.711.890.00
Change in Working Capital0.001.900.181.871.490.02
Change in Accounts Payable3.78-0.27-0.141.851.590.02
Change in Other Working Capital0.002.171.741.97-0.090.00
Other Operating Activities9.080.006.123.660.000.00
Net Cash from Operating Activities-16.01-12.25-15.95-13.56-9.500.00
Investing Activities
Net Cash from Investing Activities0.000.000.000.000.000.00
Financing Activities
Common Stock Issued0.0012.045.2931.880.000.00
Other Financing Activities29.11-0.38-1.22-4.070.000.00
Net Cash from Financing Activities29.1111.6515.0927.8115.250.00
Summary
Net Change in Cash13.10-0.59-0.8714.255.740.00
Cash at Beginning of Period18.5319.1319.995.740.000.00
Cash at End of Period31.6318.53-0.8719.995.740.00
Free Cash Flow-16.01-12.25-15.95-13.56-9.500.00